Non-coding RNA – from useless to essential
Authors:
Hana Votavová; Radim Brdička
Authors place of work:
Oddělení genomiky, Ústav hematologie a krevní transfuze, Praha
Published in the journal:
Čas. Lék. čes. 2016; 155: 370-376
Category:
Review Articles
Summary
Whole-genome sequencing analyses revealed that the majority of the human genome is transcribed and identified thousands of protein non-coding transcripts. Non-coding RNAs (ncRNAs) are divided into two main groups: small and long ncRNAs. This review is focused on the regulatory ncRNAs mainly on microRNAs and long ncRNAs. These ncRNAs regulate gene expression at the transcriptional and post-transcriptional levels. In this context, ncRNAs are involved in the regulation of most cellular processes and their deregulation has serious impacts on the phenotype. Hundreds of studies have implicated ncRNAs in the pathogenesis of many diseases ranging from metabolic disorders to diseases of organ systems as well as various types of cancers.
Clinically, ncRNAs belong to a new generation of diagnostic and prognostic biomarkers with a great potential. Due to high tissue specificity and ability to regulate multiple genes often within one signaling pathway, ncRNAs represent attractive therapeutic targets. Increasing knowledge about a wide spectrum of ncRNA actions demonstrate a pivotal role of these transcripts in expression regulation. Many aspects of the ncRNA biology are still unclear and their understanding will provide us a new perspective on the complexity of the regulatory network.
Keywords:
non-coding RNA, gene expression regulation, miRNA, lncRNA
Zdroje
1. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642–655.
2. Chang TC, Yu D, Lee YS et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43–50.
3. Cao Q, Li YY, He WF et al. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics 2013; 45: 1206–1214.
4. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008; 320: 97–100.
5. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, pimonitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143–159.
6. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524-15529.
7. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101: 2999–3004.
8. Slabý O, Svoboda M a kol. MikroRNA v onkologii. Galén, Praha, 2012.
9. Roth W, Hecker D, Fava E. Systems biology approaches to the study of biological networks underlying Alzheimer's disease: role of miRNAs. Methods Mol Biol 2016; 1303: 349–377.
10. Saghazadeh A, Rezaei N. MicroRNA machinery in Parkinson's disease: a platform for neurodegenerative diseases. Expert Rev Neurother 2015: 1–27 [Epub ahead of print].
11. Yu AD, Wang Z, Morris KV. Long noncoding RNAs: A potent source of regulation in immunity and disease. Immunol Cell Biol 2015; 93: 277–283.
12. Beneš V, Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 2010; 50: 244–249.
13. Yin JQ, Zhao RC, Morris KV. Profiling microRNA expression with microarrays. Trends Biotechnol 2008; 26: 70–76.
14. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834–838.
15. Farazi TA, Horlings HM, Ten Hoeve JJ et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 2011; 71: 4443–4453.
16. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103: 2257–2261.
17. Osaki M, Takeshita F, Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 2008; 13: 658–670.
18. Hruštincová A, Votavová H, Dostálová Merkerová M. Circulating microRNAs: methodological aspects in detection of these biomarkers. Folia Biol (Praha) 2015; 61: 203–218.
19. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513–10518.
20. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425–436.
21. Hiyoshi Y, Schetter AJ, Okayama H et al. Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer. PLoS One 2015; 10: e0124899.
22. van der Ree MH, van der Meer AJ, van Nuenen AC et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment Pharmacol Ther 2016; 43: 102–113.
23. Fire A, Xu S, Montgomery MK et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–811.
24. Yang N, Kazazian HH jr. L1 retrotransposition is suppressed by endogenously encoded small interfering RNAs in human cultured cells. Nat Struct Mol Biol 2006; 13: 763–771.
25. Watanabe T, Totoki Y, Toyoda A et al. Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. Nature 2008; 453: 539–543.
26. Marques JT, Wang JP, Wang X et al. Functional specialization of the small interfering RNA pathway in response to virus infection PLoS Pathog 2013; 9: e1003579.
27. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 2010; 24: 195–205.
28. Varshosaz J, Farzan M. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol 2015; 21: 12022–12041.
29. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011; 6: 1130–1146.
30. Aravin AA, Lagos-Quintana M, Yalcin A et al. The small RNA profile during Drosophila melanogaster development. Dev Cell 2003; 5: 337–350.
31. Iwasaki YW, Siomi MC, Siomi H. PIWI-interacting RNA: its biogenesis and functions. Annu Rev Biochem 2015; 84: 405–433.
32. Di Giacomo M, Comazzetto S, Saini H et al. Multiple epigenetic mechanisms and the piRNA pathway enforce LINE1 silencing during adult spermatogenesis. Mol Cell 2013; 50: 601–608.
33. Juliano C, Wang J, Lin H. Uniting germline and stem cells: the function of PIWI proteins and the piRNA pathway in diverse organisms. Annu Rev Genet 2011; 45: 447–469.
34. Lee JT, Bartolomei MS. X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell 2013; 152: 1308–1323.
35. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629–641.
36. Šána J, Faltejsková P, Svoboda M, Slabý O. Novel classes of non-coding RNAs and cancer. J Transl Med 2012; 10: 103.
37. Zhang Y, Liu XS, Liu QR, Wei L. Genome-wide in silico identification and analysis of cis natural antisense transcripts (cis-NATs) in ten species. Nucleic Acids Res 2006; 34: 3465–3475.
38. Tsai MC, Manor O, Wan Y et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329: 689–693.
39. Zhou J, Yang L, Zhong T et al. H19 lncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase. Nat Commun 2015; 6: 10221.
40. Keniry A, Oxley D, Monnier P et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol 2012; 14: 659–665.
41. Martianov I, Ramadass A, Serra Barros A et al. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature 2007; 445: 666–670.
42. Huarte M, Guttman M, Feldser D et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142: 409–419.
43. Huang L, Liao LM, Liu AW et al. Overexpression of long noncoding RNA HOTAIR predicts a poor prognosis in patients with cervical cancer. Arch Gynecol Obstet 2014; 290: 717–723.
44. Wang B, Su Y, Yang Q et al. Overexpression of long non-coding RNA HOTAIR promotes tumor growth and metastasis in human osteosarcoma. Mol Cells 2015; 38: 432–440.
45. Loewen G, Jayawickramarajah J, Zhuo Y, Shan B. Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol 2014; 7: 90.
46. Tripathi V, Ellis JD, Shen Z et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010; 39: 925–938.
47. Guo F, Yu F, Wang J et al. Expression of MALAT1 in the peripheral whole blood of patients with lung cancer. Biomed Rep 2015; 3: 309–312.
48. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important 3′ end functional motif in colorectal cancer metastasis. Int J Oncol 2011; 39: 169–175.
49. Pang EJ, Yang R, Fu XB, Liu YF. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol 2015; 36: 2403–2407.
50. Cabili MN, Trapnell C, Goff L et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011; 25: 1915–1927.
51. de la Taille A. Progensa PCA3 test for prostate cancer detection. Expert Rev Mol Diagn 2007; 7: 491–497.
52. Wu Y, Lu W, Xu J et al. Prognostic value of long non-coding RNA MALAT1 in cancer patients. Tumour Biol 2016; 37(1) :897–903.
53. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther 2010; 12(5): 607–616.
54. Guo F, Li Y, Liu Y et al. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin (Shanghai) 2010; 42: 224–229.
55. Ruepp A, Kowarsch A, Schmidl D et al. PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes. Genome Biology 2010, 11: R6.
56. Chen G, Wang Z, Wang D et al. LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Research 2013; 41(Database issue): D983–D986.
57. Han Li C, Chen Y. Small and long non-coding RNAs: novel targets in perspective cancer therapy. Curr Genomics 2015; 16: 319–326.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- The secular trend in body height and weight in the adult population in the Czech republic
- Correct indications and performing of autopsies in the Czech republic
- Clinical evaluation of acid-base status: Henderson-Hasselbalch, or Stewart-Fencl approach?
- The challenges of diagnostic reasoning or "how doctors think"